Use of domperidone as an off-label galactagogue is common in clinical practice, prompting questions about its overall patient safety. The issue of Domperidone safety lactation recently received scrutiny from a major retrospective cohort study. This study specifically evaluated the risk of severe postpartum mental health outcomes associated with initiating the drug.
Study Design and Population
The retrospective study included individuals in Ontario, Canada, who had a birth between March 1, 2006, and March 1, 2022. Investigators examined those who filled a domperidone prescription within 56 days of delivery. Researchers matched these individuals 1:1 using propensity scores to an unexposed group. Overall, the study identified 7,096 individuals who filled a prescription out of 2.2 million births. Ultimately, the analysis compared 4,585 domperidone-exposed individuals with an equal number of matched, unexposed individuals. Therefore, the baseline characteristics were well-balanced between the two groups.
Primary Findings on Domperidone Safety Lactation
The primary outcome assessed was any healthcare contact for incident psychosis within 365 days. Moreover, the study found no association between domperidone use and new-onset psychosis. Specifically, the rate was 6.4/1,000 person-years for both the exposed and unexposed groups (Hazard Ratio [HR] 1.00, 95% CI, 0.60-1.67). Similarly, the secondary outcome examined emergency department (ED) visits or hospitalisations for any mental health diagnosis. Importantly, the risk remained statistically insignificant for this outcome too. The rates were 38.0/1,000 person-years for the exposed group versus 43.4/1,000 person-years for the unexposed group (HR 0.88, 95% CI, 0.71-1.08). Consequently, the study concluded that initiating domperidone postpartum was not linked to a higher risk of severe mental health crises.
Clinical Context for Indian Practitioners
Indian physicians frequently prescribe domperidone as a galactagogue for managing insufficient milk supply. The findings from this large cohort study offer considerable reassurance regarding its neuropsychiatric safety profile in the postpartum setting. However, clinicians must also remember that domperidone’s primary safety concern internationally involves cardiac adverse effects. Because of the known risk of QTc prolongation, the US Food and Drug Administration (FDA) has not approved the drug for this indication. Nevertheless, the drug remains a common and generally safe option for increasing prolactin levels to enhance lactation when used judiciously and at appropriate doses. Therefore, doctors should weigh the known cardiac risks against the benefit of promoting exclusive breastfeeding.
Frequently Asked Questions
Q1: What was the primary safety question regarding domperidone in this study?
The study primarily aimed to evaluate whether postpartum domperidone use was associated with new-onset psychosis in the subsequent year.
Q2: Did the study find an association between domperidone and severe mental health events?
No. The study found no association between initiating domperidone postpartum and an increased risk of new-onset psychosis or psychiatric emergency department visits or hospitalisations.
Q3: How was the study conducted?
This was a retrospective cohort study of individuals in Ontario, Canada, who filled a domperidone prescription within 56 days of delivery, matched to an equal number of unexposed individuals.
References
- Zipursky J et al. Domperidone Use in Lactation and Risk of Severe Postpartum Mental Health Outcomes. Obstet Gynecol. 2025 Dec 11. doi: 10.1097/AOG.0000000000006142. PMID: 41380161.
- Grzeskowiak LE, Amir LH, Geddes DT. Domperidone for lactating women: an evidence-based review of adverse events and drug interactions. J Hum Lact. 2023 Feb;39(1):154-165.
- Karra M, et al. Oral domperidone versus placebo for enhancing exclusive breastfeeding among post-lower segment cesarean section mothers – a double-blind randomised controlled trial. J Matern Fetal Neonatal Med. 2023 Dec;36(1):2185754.
- Information about Domperidone. U.S. Food and Drug Administration. Updated December 12, 2023.